Physician profile
Olakunle O Akinboboye
NPI 1780632844
$382,239.48
in general payments reported to CMS, 2019-2025
60 companies · $126K in 2025
The $126K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $38K · 2021: $28K · 2022: $19K · 2023: $68K · 2024: $89K · 2025: $126K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $212K · Consulting Fee: $31K · Travel and Lodging: $27K · Food and Beverage: $14K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $211,886.50 |
| Consulting Fee | $31,229.44 |
| Travel and Lodging | $26,955.41 |
| Food and Beverage | $13,847.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $232,271.10 | 2019-2025 | Amvuttra, Onpattro |
| Pfizer INC. | $49,180.32 | 2019-2025 | |
| Akcea Therapeutics, INC. | $37,579.45 | 2019-2021 | |
| Bridgebio Pharma, INC. | $14,022.52 | 2025 | Attruby |
| Jazz Pharmaceuticals INC. | $12,955.39 | 2019-2023 | Xywav |
| Astrazeneca Pharmaceuticals Lp | $11,989.87 | 2019-2025 | Wainua, Farxiga, Lokelma |
| Amgen INC. | $4,437.95 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $4,129.22 | 2019-2025 | Verquvo, Capvaxive |
| Sobi, INC | $2,814.00 | 2021-2022 | |
| Novo Nordisk INC | $1,717.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $1,395.56 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,181.58 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,171.45 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $958.02 | 2021-2025 | |
| Janssen Research & Development, LLC | $847.04 | 2023 |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $755.98 | 2019-2022 | |
| Lilly USA, LLC | $738.38 | 2019-2025 | Mounjaro, Zepbound |
| Vivaquant INC, Dba Rhythm Express | $728.02 | 2025 | Rhythm Express |
| E.R. Squibb & Sons, L.L.C. | $461.29 | 2019-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $325.86 | 2019-2025 | Freestyle Libre 2, Aveir, Mitraclip |
| Dexcom, INC. | $288.08 | 2021-2023 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $244.37 | 2019-2021 | |
| Medtronic, INC. | $195.51 | 2022 | |
| Edwards Lifesciences Corporation | $180.73 | 2022-2025 | Sapien 3 Ultra Resilia |
| Actelion Pharmaceuticals US, INC. | $169.69 | 2023-2025 | Opsumit |
| Lexicon Pharmaceuticals, INC. | $162.71 | 2023-2024 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $144.39 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $139.28 | 2019-2024 | Livalo |
| Esperion Therapeutics, INC. | $94.76 | 2020-2025 | Nexletol |
| Mannkind Corporation | $83.06 | 2022 | |
| Global Blood Therapeutics, INC. | $79.34 | 2020 | |
| Arbor Pharmaceuticals, INC. | $69.00 | 2019-2021 | |
| Boston Scientific Corporation | $66.83 | 2022-2023 | Lux-Dx Insertable Cardiac Monitor |
| Scpharmaceuticals INC. | $63.20 | 2024-2025 | |
| Cvrx, INC. | $59.91 | 2023 | Barostim Neo System |
| Vivus LLC | $56.91 | 2019 | |
| Baxter Healthcare | $49.75 | 2023-2025 | Hillrom - Connex Spot Monitor, Hillrom - Carnation Ambulatory Monitor |
| Kestra Medical Technology Services, INC. | $46.86 | 2024 | Assure Wcd |
| Allergan, INC. | $37.22 | 2019 | |
| Currax Pharmaceuticals LLC | $33.01 | 2021 | |
| Acarix USA INC. | $31.06 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $30.83 | 2019 | |
| Exact Sciences Corporation | $28.01 | 2024 | Cologuard Collection Kit |
| Bardy Diagnostics, INC. | $25.00 | 2021 | |
| Biogen, INC. | $24.96 | 2021 | |
| Biocompatibles, INC. | $24.05 | 2019 | |
| Glaxosmithkline, LLC. | $23.69 | 2022 | |
| Astellas Pharma US INC | $22.36 | 2019 | |
| Medicomp INC | $21.62 | 2022 | |
| Genentech USA, INC. | $18.16 | 2019 | |
| Lundbeck LLC | $17.22 | 2019 | |
| Azurity Pharmaceuticals, INC. | $16.73 | 2023 | Edarbi |
| Renalytix Ai, INC. | $15.79 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Itamar Medical INC | $14.82 | 2021 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$237,414.07 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olakunle Akinboboye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.